NCT03437161

Brief Summary

This phase II trial studies how well deep inspiratory breath hold or prone breast radiation therapy works in reducing cardiac dose in patients with breast cancer or ductal carcinoma in situ. Deep inspiratory breath hold is a technique that involves a patient holding their breath during radiation to move the heart away from the breast to minimize radiation to the heart. Prone breast radiation therapy is a technique in which a patient receives treatment "face-down" to minimize the radiation to the rest of the body, including the heart and lungs. Comparing deep inspiratory breath hold to prone breast radiation therapy may help doctors improve radiation to the target while reducing radiation to healthy tissues surrounding the target.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable breast-cancer

Timeline
Completed

Started Jan 2017

Longer than P75 for not_applicable breast-cancer

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 17, 2017

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 26, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 5, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 19, 2018

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2023

Completed
Last Updated

February 17, 2023

Status Verified

February 1, 2023

Enrollment Period

8 months

First QC Date

February 5, 2018

Last Update Submit

February 16, 2023

Conditions

Keywords

RadiationProne positionSupine positionDIBHInvasive Breast CarcinomaDuctal Breast Carcinoma In Situ

Outcome Measures

Primary Outcomes (1)

  • Mean cardiac dose

    Assess whether the mean cardiac dose in the supine DIBH plan differs from the mean cardiac dose in the prone plan within strata defined by total RT dose.

    Up to 6 weeks

Secondary Outcomes (12)

  • Volume of heart receiving > 20 gray (Gy)

    Up to 6 weeks

  • Mean left anterior descending artery (LAD) dose in DIBH plan vs. prone plan

    Up to 6 weeks

  • Maximum left anterior descending artery (LAD) dose in DIBH plan vs. prone plan

    Up to 6 weeks

  • Mean ipsilateral lung dose

    Up to 6 weeks

  • Volume of ipsilateral lung receiving > 20Gy

    Up to 6 weeks

  • +7 more secondary outcomes

Study Arms (1)

Radiation Therapy (RT)

EXPERIMENTAL

Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.

Radiation: Radiation Therapy (RT)

Interventions

Undergo RT either in the supine position with DIBH or in the prone position.

Also known as: Cancer Radiotherapy, Radiotherapy, RT
Radiation Therapy (RT)

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Any woman with biopsy proven left breast DCIS or invasive cancer who has undergone a lumpectomy and who requires whole breast irradiation to the breast alone (and not to any nodal regions) as per the treating radiation oncologist

You may not qualify if:

  • Previous radiation to the ipsilateral breast
  • All pre-menopausal women will require a urine qualitative pregnancy test to exclude pregnancy; pregnant women will be excluded from the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast NeoplasmsDeceptionCarcinoma, Intraductal, Noninfiltrating

Interventions

RadiotherapyRadiation

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesSocial BehaviorBehaviorAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeBreast Carcinoma In SituCarcinoma in SituNeoplasms, Ductal, Lobular, and Medullary

Intervention Hierarchy (Ancestors)

TherapeuticsPhysical Phenomena

Study Officials

  • Naamit Gerber, MD

    Laura and Isaac Perlmutter Cancer Center at NYU Langone

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2018

First Posted

February 19, 2018

Study Start

January 17, 2017

Primary Completion

September 26, 2017

Study Completion

February 15, 2023

Last Updated

February 17, 2023

Record last verified: 2023-02